EUVIMEDEUVIMED entdecken
Crossref

Real‐world experience of budesonide orodispersible tablets in pediatric eosinophilic esophagitis

Saverio Pochesci iD, Camilo Maza Angulo, Heather Grant, Richard K Russell

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Saverio Pochesci und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children & Young People, Edinburgh, UK. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Budesonide, Anti-Inflammatory Agents. Die Arbeit nennt 18 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We retrospectively evaluated the effectiveness of budesonide orodispersible tablets (BOT) in children with eosinophilic esophagitis (EoE) followed up at our center. A total of 17 children were treated with BOT 0.5 mg twice daily after a median time from diagnosis of 16 months (interquartile range [IQR]: 11–28.5). Previous treatments included proton‐pump inhibitors, food elimination diets, and topical swallowed corticosteroids (TSC). After 3 months, 11/17 (65%) patients were in clinical remission. 8/17 (47%) patients repeated an endoscopy after a median time of 11.5 months (6.75–16.75 IQR); 6/8 (75%) were in endoscopic remission and 7/8 (87.5%) achieved histological remission. Eosinophils count at histology significantly decreased from baseline (30 [15–50 IQR] to 6 [6–9 IQR], p = 0.03]. 3/4 (75%) patients who previously failed TSC achieved complete remission on BOT. After a median follow‐up of 12.5 months (6.25–21 IQR), 11/17 (65%) patients were still on BOT treatment, and 9/11 (82%) were in clinical remission. No adverse events were reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisBudesonideAnti-Inflammatory AgentsHumansFemaleChildMaleRetrospective StudiesTreatment OutcomeTabletsChild, PreschoolRemission InductionAdministration, OralFollow-Up StudiesEosinophilsAdolescentEsophagoscopy

Stichwörter der Autor:innen

childreneosinophilsesophageal inflammationtopical corticosteroids

Substanzen

BudesonideTabletsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children & Young People, Edinburgh, UK.
  • Amsterdam UMC, Amsterdam, the Netherlands.
  • Dietetics Department, Royal Hospital for Children & Young People, Edinburgh, UK.
  • Child Life and Health, University of Edinburgh, Royal Hospital for Children & Young People, Edinburgh, UK.

ORCID-Profile: Saverio Pochesci

Förderung

  • None

Zitieren

APA

Pochesci, S., Maza Angulo, C., Grant, H., & Russell, R. K. (2026). Real‐world experience of budesonide orodispersible tablets in pediatric eosinophilic esophagitis. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70359

Vancouver

Pochesci S, Maza Angulo C, Grant H, Russell RK. Real‐world experience of budesonide orodispersible tablets in pediatric eosinophilic esophagitis. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70359

BibTeX
@article{Pochesci2026,
  author = {Pochesci, Saverio and Maza Angulo, Camilo and Grant, Heather and Russell, Richard K},
  title = {Real‐world experience of budesonide orodispersible tablets in pediatric eosinophilic esophagitis},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70359}
}
Kostenlos starten →